September 30, 2026

#antiviral — Wednesday, September 30, 2026 (2 items)

hot top new

2		ℹ	8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India. (linkinghub.elsevier.com)	Goel A … Aggarwal R The Lancet 2026-09-30	#hepatitis c #clinical trial #antiviral #treatment #viremia
1		ℹ	The circSNX6 restricts dengue virus replication in association with PARP1 and ferroptosis. (pnas.org)	Tang R … Sun Q PNAS 2026-09-30	#dengue #ferroptosis #ncrna #antiviral #immunity